David Laskow-Pooley
Chairman (2017, elected 2016)
Born: 1954
Education: BSc Pharmacy (1st), Pharmaceutical/ Chemical engineering specialty and QP., Sunderland School of Pharmacy.
Other ongoing assignments: Director of the Board of Marker Therapeutics Inc., USA, Pharmafor Ltd., and LREsystem Ltd. Chairman of the Board of OSPT Ltd., UK.
Previous assignments in the last five years: QP in HMR Ltd.
No. of shares in Abliva: 45,828.
Other: Non-affiliated to the Company, the management and to major owners.
David Bejker
Director (2017)
Born: 1975
Education: M.Sc. (Econ.), Stockholm School of Economics.
Other ongoing assignments: Director of the Board of LIDDS AB and Amylonix AB, and CEO of Affibody Medical AB.
Previous assignments in the last five years: –
No. of shares in Abliva: 136,360.
Other: Non-affiliated to the Company, the management and to major owners.
Roger Franklin
Director (2020)
Born: 1979
Education: M.Biochem (1st class), Molecular & Cellular Biochemistry, University of Oxford (UK), PhD, MRC Laboratory of Molecular Biology from University of Cambridge (UK).
Other ongoing assignments: Partner at Hadean Ventures. Director at Gesynta Pharma AB, Crosslanes Holding AB and TargED Biopharmaceuticals B.V. Deputy Director at HVentures AB, HVentures Capital I AB and HVentures Capital II AB. Board observer at Step Pharma SAS, Pipeline Therapeutics Inc, Emergence Therapeutics AG, and Cardior Pharmaceuticals GmbH.
Previous assignments over the past five years: Deputy Director at Saga Diagnostics AB.
No. of shares in Abliva: 237,030,157 (owned by legal entities related to the director).
Other: Non-affiliated to the company and the management, but not to major owners.
Denise Goode
Director (2018)
Born: 1958
Education: Institute of Chartered Accountants in England and Wales Chartered Accountant. B.Sc. Zoology from The University of Manchester (UK).
Other ongoing assignments: Director of the Board and CEO of QED Life Sciences Limited, Director of the Board at Alligator Bioscience, and VP Business Development at AnaMar AB.
Previous assignments in the last five years: Director of the Board of Dechra Pharmaceuticals PLC and OBN Ltd. (UK).
No. of shares in Abliva: –
Other: Non-affiliated to the company, the management, and to major owners.
Jan Törnell
Director (2017)
Born: 1960
Education: MD and PhD in physiology, University of Gothenburg.
Other ongoing assignments: CEO and Director of the Board of Innoext AB. Chairman of the Board of LIDDS AB, Isofol Medical AB, and Glactone Pharma AB. Director of the Board of Diaprost AB, and Deputy Director of the Board of LIDDS Pharma AB.
Previous assignments over the past five years: Director of the Board of Hammars Bryggförening, Diaprost AB and Stayble Therapeutics AB. CEO of Oncorena AB. Partner in P.U.L.S. AB.
No. of shares in Abliva: 62,492.
Other: Non-affiliated to the Company, the management and to major owners.